Keyphrases
Acute Episodes
33%
Central Nervous System
100%
Central Nervous System Demyelinating Diseases
33%
Delphi Method
33%
Demyelinating Diseases
100%
Diagnosis Treatment
33%
Diagnostic Evaluation
33%
Disease-modifying Therapy
33%
Expert Panel
33%
Glatiramer Acetate
33%
Immune-mediated Inflammatory Diseases
33%
Interferon-α (IFN-α)
33%
Methylprednisolone
33%
Neurologist
100%
Pediatric
100%
Pediatric multiple Sclerosis
33%
Perceived Efficacy
33%
Practice Patterns
33%
Tolerability
33%
Treatment Choice
33%
Treatment Duration
33%
Treatment Use
33%
United States
100%
Medicine and Dentistry
Adolescence
33%
Central Nervous System
100%
Clinically Isolated Syndrome
100%
Demyelinating Disorder
100%
Disease Modifying Therapy
33%
Diseases
33%
Glatiramer
33%
Inflammatory Disorder
33%
Interferon
33%
Methylprednisolone
33%
Multiple Sclerosis
33%
Pediatrics
100%
Treatment Duration
33%
Neuroscience
Central Nervous System
100%
Demyelinating Disease
100%
Demyelinating Disorder
100%
Glatiramer Acetate
33%
Interferon
33%
Methylprednisolone
33%
Multiple Sclerosis
33%
Pharmacology, Toxicology and Pharmaceutical Science
Demyelinating Disease
75%
Disease
100%
Glatiramer
25%
Interferon
25%
Methylprednisolone
25%
Multiple Sclerosis
25%
Tolerability
25%